WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIIB

Based on 22 analysts offering 12 month price targets for Biogen Inc

Min Forecast
$150.00-27.41%
Avg Forecast
$228.27+10.47%
Max Forecast
$280.00+35.51%

Should I buy or sell BIIB stock?

Based on 22 analysts offering ratings for Biogen Inc.

Buy
Strong Buy
8 analysts 36.36%
Buy
5 analysts 22.73%
Hold
8 analysts 36.36%
Sell
1 analysts 4.55%
Strong Sell
0 analysts 0%
Although BIIB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BIIB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their BIIB stock forecasts and price targets.

BIIB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-04
lockedlocked$00.00+00.00%2026-08-03
lockedlocked$00.00+00.00%2026-07-30
lockedlocked$00.00+00.00%2026-07-30
lockedlocked$00.00+00.00%2026-07-30
RBC Capital
Top 10%
91
BuyMaintains$240.00+16.15%2026-07-30
Canaccord Genuity
Top 18%
83
Strong BuyMaintains$248.00+20.02%2026-07-30
TD Cowen
Top 16%
85
Strong BuyMaintains$225.00+8.89%2026-07-30
Wedbush
Top 3%
98
HoldMaintains$215.00+4.05%2026-07-30
Barclays
Top 41%
60
HoldMaintains$200.00-3.21%2026-07-29

1 of 3

Forecast return on equity

Is BIIB forecast to generate an efficient return?

Company
16.36%
Industry
10.09%
Market
178.03%
BIIB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIIB forecast to generate an efficient return on assets?

Company
9.61%
Industry
28.93%
BIIB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIIB earnings per share forecast

What is BIIB's earnings per share in the next 3 years based on estimates from 39 analysts?

Avg 1 year Forecast
$13.17+131.79%
Avg 2 year Forecast
$16.77+195.18%
Avg 3 year Forecast
$18.70+229.2%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BIIB revenue forecast

What is BIIB's revenue in the next 3 years based on estimates from 38 analysts?

Avg 1 year Forecast
$10.5B+4.78%
Avg 2 year Forecast
$10.7B+6.98%
Avg 3 year Forecast
$11.0B+10.01%
BIIB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIIB earnings growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
49.64%
Industry
32.03%
Market
32.36%
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BIIB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BIIB revenue growth forecast

How is BIIB forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
3.18%
Industry
8.34%
Market
13.78%
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIIB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIIB vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BIIB$206.63$228.27+10.47%Buy
GRFS$7.93N/AN/A
OGN$13.57$12.00-11.57%Sell
AMRN$14.41N/AN/A
SCLX$6.52N/AN/A
View Top General Drug Manufacturer Stocks

Biogen Stock Forecast FAQ

Is Biogen Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 22 Wall Street analysts covering (NASDAQ: BIIB) stock is to Buy BIIB stock.

Out of 22 analysts, 8 (36.36%) are recommending BIIB as a Strong Buy, 5 (22.73%) are recommending BIIB as a Buy, 8 (36.36%) are recommending BIIB as a Hold, 1 (4.55%) are recommending BIIB as a Sell, and 0 (0%) are recommending BIIB as a Strong Sell.

If you're new to stock investing, here's how to buy Biogen stock.

What is BIIB's earnings growth forecast for 2026-2028?

(NASDAQ: BIIB) Biogen's forecast annual earnings growth rate of 49.64% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 32.03%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.36%.

Biogen's earnings in 2026 is $834,600,000.On average, 39 Wall Street analysts forecast BIIB's earnings for 2026 to be $1,945,240,485, with the lowest BIIB earnings forecast at $1,600,028,044, and the highest BIIB earnings forecast at $2,446,584,576. On average, 39 Wall Street analysts forecast BIIB's earnings for 2027 to be $2,477,302,632, with the lowest BIIB earnings forecast at $2,054,696,647, and the highest BIIB earnings forecast at $3,118,348,128.

In 2028, BIIB is forecast to generate $2,762,807,682 in earnings, with the lowest earnings forecast at $2,241,487,251 and the highest earnings forecast at $3,614,801,561.

What is BIIB's revenue growth forecast for 2026-2028?

(NASDAQ: BIIB) Biogen's forecast annual revenue growth rate of 3.18% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.

Biogen's revenue in 2026 is $10,027,900,000.On average, 38 Wall Street analysts forecast BIIB's revenue for 2026 to be $1,552,451,256,986, with the lowest BIIB revenue forecast at $1,397,605,067,082, and the highest BIIB revenue forecast at $1,661,345,953,512. On average, 38 Wall Street analysts forecast BIIB's revenue for 2027 to be $1,585,104,890,544, with the lowest BIIB revenue forecast at $1,422,279,984,748, and the highest BIIB revenue forecast at $1,726,357,712,632.

In 2028, BIIB is forecast to generate $1,630,022,105,936 in revenue, with the lowest revenue forecast at $1,429,372,176,652 and the highest revenue forecast at $1,836,729,949,138.

What is BIIB's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BIIB) forecast ROA is 9.61%, which is lower than the forecast US Drug Manufacturers - General industry average of 28.93%.

What is BIIB's Price Target?

According to 22 Wall Street analysts that have issued a 1 year BIIB price target, the average BIIB price target is $228.27, with the highest BIIB stock price forecast at $280.00 and the lowest BIIB stock price forecast at $150.00.

On average, Wall Street analysts predict that Biogen's share price could reach $228.27 by Aug 4, 2027. The average Biogen stock price prediction forecasts a potential upside of 10.47% from the current BIIB share price of $206.63.

What is BIIB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BIIB) Biogen's current Earnings Per Share (EPS) is $5.68. On average, analysts forecast that BIIB's EPS will be $13.17 for 2026, with the lowest EPS forecast at $10.83, and the highest EPS forecast at $16.56. On average, analysts forecast that BIIB's EPS will be $16.77 for 2027, with the lowest EPS forecast at $13.91, and the highest EPS forecast at $21.11. In 2028, BIIB's EPS is forecast to hit $18.70 (min: $15.17, max: $24.47).

What is BIIB's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BIIB) forecast ROE is 16.36%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.